Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study

Chest

Volumn 140, Issue 5, 2011, Pages 1274-1283

  Rubin, Lewis J ^a   Badesch, David B ^b   Fleming, Thomas R ^c   Galiè, Nazzareno ^d   Simonneau, Gerald ^e   Ghofrani, Hossein A ^f   Oakes, Michael ^g   Layton, Gary ^g   Serdarevic Pehar, Marjana ^g   McLaughlin, Vallerie V ^h   Barst, Robyn J ⁱ  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; SILDENAFIL;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; BRONCHITIS; CHEST TIGHTNESS; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYANOSIS; DEATH; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FLUSHING; FUNCTIONAL STATUS; GASTRITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GRAND MAL SEIZURE; HEART MURMUR; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPEREMIA; HYPOKALEMIA; HYPOTENSION; INFLUENZA; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; JAW PAIN; LIMB PAIN; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE CRAMP; MUSCLE STIFFNESS; MYALGIA; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RETINA HEMORRHAGE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SUBCAPSULAR CATARACT; SURVIVAL RATE; SYNCOPE; TOOTH PAIN; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VERTIGO; VISUAL DISORDER; VISUAL FIELD DEFECT; VOMITING; WALKING; WEIGHT GAIN;

EID: 80052088060     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-0969     Document Type: Article

References (23)

1. Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002;20(5):1314-1331. (Pubitemid 35339335)
2. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928. (Pubitemid 46981654)
3. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(suppl):S78-S84.
4. Galiè N, Humbert M, Vachiéry JL, et al. Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002; 39 (9):1496-1502.
5. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension . J Am Coll Cardiol. 2003; 41(12):2119-2125. (Pubitemid 36724255)
6. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108(17):2066-2069. (Pubitemid 37337580)
7. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105(20):2398-2403. (Pubitemid 34556392)
8. Zimmermann AT, Calvert AF, Veitch EM. Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J. 2002;32(8):424-426.
9. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43(7):1149-1153. (Pubitemid 38452588)
10. Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. 2003;55(1):55-59. (Pubitemid 36582684)
11. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 42(1):158-164. (Pubitemid 36760778)
12. Kuhn KP, Wickersham NE, Robbins IM, Byrne DW. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lung Res. 2004;30(2): 135-145. (Pubitemid 38293714)
13. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-694. (Pubitemid 46331988)
14. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157. (Pubitemid 41653106)
15. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223. (Pubitemid 17137857)
16. Galiè N, Brundage BH, Ghofrani HA, et al. Pulmonary Arterial Hypertension and Response to Tadalafil(PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22):2894-2903.
17. Jing ZC, Xu XQ, Badesch DB, et al. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med. 2009;103(8):1136-1142.
18. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788. (Pubitemid 34925627)
19. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
20. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension . Eur Respir J. 2005;25(2):244-249. (Pubitemid 40246523)
21. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008;134(4):775-782.
22. Helman DL Jr, Brown AW, Jackson JL, Shorr AF. Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: potential implications for the design of future clinical trials. Chest. 2007;132(3):764-772.
23. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4): 394-403.